ADAR1 Capital Management, LLC

Position in ATYR — aTYR PHARMA INC

CIK 1940272 AUSTIN, TX

Back to ATYR Full portfolio

Position in ATYR

as of Mar 31, 2026 · filed May 18, 2026 Compact

Position Value

$39,534

-$152 QoQ

Shares Held

50,685

0.0% QoQ

Ownership

0.052%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#31

of 109 holders

Holding Since

Jun 2025

4 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ATYR Over Time

Shares Held

Position Value (USD)

Derivatives in ATYR

reported options exposure · as of Sep 30, 2025

CallValue

$61,140

CallShares

84,800

PutValue

$160,422

PutShares

222,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

ADAR1 Capital Management, LLC holds $1,358,750,123 across 211 Biotechnology names. ATYR ranks #206 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ABVX	Abivax S.A.	1,394,019	$155,224,015
2	PTGX	Protagonist Therapeutics, Inc	994,119	$104,780,142
3	ROIV	Roivant Sciences Ltd.	3,285,906	$91,019,596
4	IMVT	Immunovant, Inc.	2,679,010	$66,546,608
5	TERN	Terns Pharmaceuticals, Inc.	914,699	$48,222,931
6	CYTK	Cytokinetics Inc	632,556	$41,691,765
7	CRNX	Crinetics Pharmaceuticals, Inc.	1,139,331	$41,380,501
8	DNLI	Denali Therapeutics Inc.	1,871,455	$35,931,936

All Filings in ATYR

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$39,534	50,685	0.0%	Shares	Sole	2026-05-18
2025-12-31	$39,686	50,685	-77.2%	Shares	Sole	2026-02-18
2025-09-30	$160,422	222,500	+27.1%	Put	Sole	2025-11-14
2025-09-30	$126,175	175,000	+106.4%	Shares	Sole	2025-11-14
2025-09-30	$61,140	84,800	+69.6%	Call	Sole	2025-11-14
2025-06-30	$253,500	50,000	—	Put	Sole	2025-08-14
No filing history on record for this holder in this stock.